pocketful logo light
pocketful logo light
Sun Pharma Advanced Research Company Ltd logo

Sun Pharma Advanced Research Company Ltd

NSE: SPARC BSE: 532872

₹204.22

(0.83%)

Tue, 16 Jun 2026, 00:32 am

mtf coin illustrationMTF 5x

Sun Pharma Advanced Research Company Share Price Live Chart

1 Day

(0.83%)

No Result Found

Summary

  • Market Cap (in Cr)

    6876.61

  • Net Profit (in Cr)

    -342.51

  • P/B

    -22.16

  • Sector P/E

    33.76

  • P/E

    -14.03

  • EV/EBITDA

    0

  • Debt/Equity (Industry)

    0.63

  • Interest Cover (Industry)

    1.51

  • ROCE (Industry)

    0.04

  • RONW (Industry)

    0.02

  • ROE

    0

  • ROCE

    0

  • Debt/Equity

    0

  • EPS (TTM)

    48.24

  • Dividend Yield

    0

  • Book Value

    41.26

  • Interest Cover

    -36.92

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters65.6765.6765.6765.6765.67
FII2.042.041.761.471.45
DII0.880.781.050.971.13
Public31.4131.5031.5231.8831.75
Government0.000.000.000.000.00

Read More

Technical Analysis

RSI

66.62

MACD

13.58

50 DMA

171.19

200 DMA

143.12

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic419.59309.76260.93199.93151.1090.10-
Fibonacci309.76267.80241.88199.93157.97132.0590.10
Camarilla242.31232.25222.18199.93202.04191.97181.91

Pivots Level: Classic

R3

+219.66

419.59

R2

+109.83

309.76

R1

+61.01

260.93

199.93
199.93
Pivot Point
LTP: 229.03

S1

-48.82

151.10

S2

-109.83

90.10

S3

-199.93

-

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    212.86

  • 20-EMA

    203.33

  • 30-EMA

    193.87

  • 50-EMA

    179.43

  • 100-EMA

    161.74

  • 200-EMA

    154.07

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
18 May 2026board-meetingsAccounts
09 Feb 2026board-meetingsQuarterly Results
16 Jan 2026egm
10 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
08 Jul 2025agm
08 Jul 2024agm
12 Jul 2023agm
26 Aug 2022agm
03 Sept 2021agm
21 Aug 2021agmAnnual General Meeting23 Sept 2021

Read More

Peer Comparison

Sun Pharma Advanced Research Company Ltd logo

Sun Pharma Advanced Research Company Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Sun Pharma Advanced Research Company Ltd About

Sun Pharma Advanced Research Company is engaged in the business of research and development (R&D) of pharmaceutical products.

Industry

Miscellaneous

Founded

2006

Headquarters

CEO

Dilip S Shanghvi

Employees

Contact

Website icon

Website

http://www.sparc.life

Email icon

Email

secretarial@sparcmail.com

Phone icon

Phone

91-265-2330815/2339257

Location icon

Location

Sun Pharma Advanced Res Centre, Akota Road Akota, Vadodara, Gujarat, 390020

Read More

Sun Pharma Advanced Research Company Ltd Company History

YearHistory
2019
  • SPARC entered into a licensing agreement with Bioprojet to acquire exclusive rights for investigational medicinal product, SCD-044.
  • SPARC entered into a licensing agreement with Bioprojet to acquire exclusive rights for investigational medicinal product.
  • HitGen and SPARC entered into a DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration.
  • SPARC received Orphan Drug Designation from the USFDA for SCO-088 for the treatment of patients with Chronic Myeloid Leukemia.
  • SPARC entered into a licensing deal with CMS.
2020
  • Sun Pharma Advanced Research Company Ltd granted an exclusive license to Tripoint Therapeutics LLC to commercialize ElepsiaTM XR 1000 mg and ElepsiaTM XR 1500 mg tablets in the USA.
  • Sun Pharma Advanced Research Company Ltd got positive top-line results from its Phase 3 trial for its investigational drug, SDN-037, for the treatment of Inflammation and Pain associated with Ocular Surgery.
  • SPARC provided an update on Clinical Programs and R&D Pipeline.
2021
  • SPARC entered into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target.
  • Sun Pharma Advanced Research Company Ltd granted exclusive worldwide rights to Visiox Pharma LLC for the development and commercialization of PDP-716 and SDN-037.
2022
  • Sun Pharma and SPARC entered into a license agreement for commercialization of phenobarbital for injection in the US.
2023
  • Sun Pharma Advanced Research Company Ltd entered into a licensing agreement to acquire exclusive rights for SCD-153.
  • Sun Pharma Advanced Research Company Ltd formed a US subsidiary.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
HRTI PRIVATE LIMITEDbulkSell1895932240.8626 May 2026
HRTI PRIVATE LIMITEDbulkBuy1986488240.5326 May 2026
JUNOMONETA FINSOL PRIVATE LIMITEDbulkSell2396273227.6125 May 2026
JUNOMONETA FINSOL PRIVATE LIMITEDbulkBuy2420817227.4925 May 2026
NK SECURITIES RESEARCH PRIVATE LIMITEDbulkBuy2217270227.4325 May 2026
QE SECURITIES LLPbulkBuy1809082227.1225 May 2026
MICROCURVES TRADING PRIVATE LIMITEDbulkBuy2128865228.3125 May 2026
HRTI PRIVATE LIMITEDbulkBuy2532120226.925 May 2026
QE SECURITIES LLPbulkSell1818961225.9825 May 2026
MICROCURVES TRADING PRIVATE LIMITEDbulkSell2128865228.3825 May 2026

Read More

Sun Pharma Advanced Research Company Ltd News

OcuVex Gets FDA Complete Response Letter for PDP-716 NDA

SPARC's partner OcuVex Therapeutics has received a Complete Response Letter from the FDA for its PDP-716 NDA due to manufacturing inspection issues.

19 May 2026

companies

SPARC Posts ₹1,55,213 Lakhs Profit in FY26 on PRV Income

Sun Pharma Advanced Research Co swings to a standalone profit of ₹1,55,213 lakhs in FY26 from a loss of ₹34,522 lakhs in FY25, driven by a ₹1,84,002 lakhs Priority Review Voucher income.

18 May 2026

companies

SPARC Sells Priority Review Voucher for $195 Million

Sun Pharma Advanced Research Company Ltd. sells FDA-granted Rare Paediatric Disease Priority Review Voucher for US $195 million to accelerate pipeline development and strengthen external innovation strategy.

01 May 2026

companies

SPARC sells Priority Review Voucher for $195 million

Sun Pharma Advanced Research Company announces sale of FDA Priority Review Voucher for US $195 million, granted for Sezaby approval for neonatal seizures treatment.

30 Apr 2026

companies

SPARC sells Priority Review Voucher for $195 million

Sun Pharma Advanced Research Company announces sale of FDA Priority Review Voucher for US $195 million, granted for Sezaby approval for neonatal seizures treatment.

30 Apr 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number